AIQ Solutions

High-Level Overview

AIQ Solutions is a Madison, Wisconsin-based healthcare software company that develops TRAQinform IQ, a FDA-cleared software medical device for analyzing radiological imaging data in late-stage cancer management.[1][2][3][4] It serves oncologists, clinicians, pharmaceutical companies for early-stage drug development, and hospital systems by quantifying changes in tumor lesions over time, enabling personalized therapy adjustments and predictions of treatment effectiveness and toxicity risks.[1][2][3] The platform addresses unmet needs in metastatic cancer care by providing 3D quantitative insights into lesion response heterogeneity, outperforming standard-of-care methods and supporting optimized clinical outcomes with easy workflow integration via HIPAA-compliant cloud uploads.[2][3]

With around 30 employees and $6.3 million in revenue, AIQ has secured under $5 million in funding, including nearly $2.7 million in SBIR grants, demonstrating steady growth from its research roots.[1][2]

Origin Story

AIQ Solutions was founded in 2015 in Madison, Wisconsin, by a team of experts from the University of Wisconsin's medical physics department—the largest in the U.S.—including Founder & CEO (name not specified in sources), Co-founder & COO, Co-founder & CTO, Jeraj, Liu, Alberti, and Starbuck, backed by 15 years of UW research and Ph.D. student contributions.[1][2] The idea emerged from a need to analyze multiple radiological images faster and more comprehensively, giving physicians better data to manage cancer patients effectively, particularly in metastatic cases where lesions respond heterogeneously to therapy.[2]

Early traction came from developing TRAQinform IQ, which evolved into a clinical tool. In late 2018, Eric Horler joined as president and CEO, steering commercialization; the company has since gained FDA clearance (510(k) K173444) and state/federal support like WEDC grants.[2][4]

Core Differentiators

• Quantitative 3D Lesion Analysis: Unlike standard-of-care, TRAQinform IQ measures treatment response heterogeneity across all cancer lesions using serial PET/CT images, predicting outcomes without predictive modeling—focusing on real patient data for precise therapy adjustments.[1][2][3]
• Workflow Ease and Compliance: Cloud-based, HIPAA-compliant uploads generate comprehensive reports quickly, integrating seamlessly into oncologist routines for late-stage care optimization.[3]
• Dual-Use Versatility: Supports pharma in early drug development (e.g., tracer assessment) and hospitals in patient therapy, with validated research backing like publications on prognostication and prostate cancer response.[3]
• Research Pedigree: Built on UW's world-class medical physics, aiming for standard-of-care status in oncology guidelines.[2]

Role in the Broader Tech Landscape

AIQ rides the wave of AI-driven precision oncology and tumor heterogeneity insights, where market forces like rising cancer prevalence, personalized medicine demands, and imaging AI advancements (e.g., quantitative PET/CT) create tailwinds.[2][3] Timing is ideal amid post-2020 regulatory nods for AI medical devices and pharma's push for faster drug pipelines, filling gaps in late-stage care neglected by screening/diagnosis tools.[3]

It influences the ecosystem by enabling data-driven decisions that could standardize lesion tracking, reduce ineffective treatments, and accelerate therapies—bolstered by Wisconsin's biotech hub status and grants fostering Midwest innovation.[2]

Quick Take & Future Outlook

AIQ is poised to expand TRAQinform IQ adoption as oncology guidelines evolve, potentially partnering with major pharma and health systems for broader validation and scale.[2][3] Trends like multimodal AI imaging, real-world evidence mandates, and value-based care will propel it, evolving its role from niche tool to ecosystem standard—building directly on its research-fueled foundation in Madison's medtech scene.[1][2]